Poxel Logo

Poxel

POXEL | PA

Overview

Corporate Details

ISIN(s):
FR0012432516
LEI:
9695003OIX0T7NX72N26
Country:
France
Address:
259 AVENUE JEAN JAURES, 69007 LYON
Sector:
Professional, scientific and technical activities
Industry:
Research and experimental development on natural sciences and engineering

Description

Poxel SA is a clinical-stage biopharmaceutical company developing treatments for metabolic diseases, with a focus on non-alcoholic steatohepatitis (NASH) and rare metabolic disorders. Its pipeline features two mid-stage candidates: PXL065 (deuterium-stabilized R-pioglitazone) for NASH, which met its primary endpoint in a Phase 2 trial, and PXL770, a first-in-class direct adenosine monophosphate-activated protein kinase (AMPK) activator for rare diseases. The company's product, TWYMEEG® (Imeglimin), was approved in 2021 and is marketed for type 2 diabetes in Japan by its partner Sumitomo Pharma, providing Poxel with royalties and sales-based payments.

Social Media

Stop Scraping. Start Analyzing.

You're viewing a fraction of the data available for Poxel. Get complete, real-time, and AI-ready data via the API the pros use.

Get Instant API & Bulk Data Access

Filings

You have of free filing views remaining. Upgrade for unlimited access.
Quick Filters:

Filters

Clear
Date Filing Language Size Actions
2025-08-08 17:45
Delisting Announcement
Inside Information / Other news releases
English 109.8 KB
2025-08-08 17:45
Legal Proceedings Report
Informations privilégiées / Autres communiqués
French 96.7 KB
2025-08-01 07:30
Legal Proceedings Report
Inside Information / Other news releases
English 134.8 KB
2025-08-01 07:30
Board/Management Information
Informations privilégiées / Autres communiqués
French 164.3 KB
2025-07-08 18:46
Declaration of Voting Results & Voting Rights Announcements
Total du nombre de droits de vote et du capital / Information relative au nombr…
French 110.8 KB
2025-06-30 18:32
Pre-Annual General Meeting Information
Inside Information / Other news releases
English 109.4 KB
2025-06-30 18:32
Regulatory News Service
Informations privilégiées / Autres communiqués
French 95.0 KB
2025-06-06 19:05
Declaration of Voting Results & Voting Rights Announcements
Total du nombre de droits de vote et du capital / Information relative au nombr…
French 76.2 KB
2025-05-28 07:30
Earnings Release
Inside Information / Other news releases
English 95.0 KB
2025-05-28 07:30
Regulatory News Service
Informations privilégiées / Autres communiqués
French 119.8 KB
2025-05-26 18:00
Regulatory News Service
Inside Information / Other news releases
English 98.0 KB
2025-05-26 18:00
Environmental & Social Information
Informations privilégiées / Autres communiqués
French 86.7 KB
2025-05-13 07:30
Earnings Release
Informations privilégiées / Information sur chiffre d’affaires annuel
French 153.8 KB
2025-05-13 07:30
Earnings Release
Inside Information / Information on annual revenues
English 130.6 KB
2025-05-06 17:45
Declaration of Voting Results & Voting Rights Announcements
Total du nombre de droits de vote et du capital / Information relative au nombr…
French 84.4 KB

Automate Your Workflow. Get a real-time feed of all Poxel filings delivered via API.

Explore Data Feeds →

Market Data

Market Data Not Available

Financials & KPIs

No data available

No Financial Data Available

Standardized financial statements for the selected period are not yet available.

Need More History? Access decades of standardized financials for Poxel via our API.

Get Historical Data →

Insider Transactions

Date Insider Name Position Type Shares Value
2024-01-29 N/A Other Buy 80,000 N/A

Peer Companies

Company Country Ticker View
1NKEMIA Logo
Offers contract R&D, develops tech platforms, and invests in life sciences ventures.
Spain IKM
2cureX AB Logo
Tests cancer drugs on patient-derived micro-tumors for personalized oncology treatments.
Sweden 2CUREX
4SC AG Logo
Developing epigenetic small-molecule drugs for cancers with high unmet medical needs.
Germany VSC
Abera Bioscience AB Logo
Develops next-gen mucosal vaccines using an OMV platform for major infectious diseases.
Sweden ABERA
ABIVAX Logo
Developing oral drugs for chronic inflammatory diseases like ulcerative colitis and Crohn's disease.
France ABVX
Abliva Logo
A clinical-stage biotech developing medicines for rare primary mitochondrial diseases.
Sweden ABLI
Achiko AG Logo
A liquidated health tech firm that developed aptamer diagnostics and a COVID-19 passport app.
Switzerland ACHI
Acticor Biotech Logo
Biopharma developing first-in-class drugs for acute stroke and other thrombotic diseases.
France ALACT
Active Biotech Logo
Develops immunotherapies for cancer and inflammatory diseases with significant unmet needs.
Sweden ACTI
Addex Therapeutics Ltd Logo
Develops oral small molecule drugs, allosteric modulators, for neurological disorders.
Switzerland ADXN